Clinical and radiographic comparison of Biodentine and Formocresol: an updated meta-analysis with trial sequential analysis
Purpose This meta-analysis aimed to compare the clinical and radiographic success rate of Biodentine as an alternative to Formocresol to provide a critical appraisal of the available literature and evidence-based conclusion as well as update the previous systematic review. Methods MEDLINE, CENTRAL, Web of Science, Scopus, and Google Scholar databases were searched up to 20 October 2021 to identify RCTs evaluating pulpotomy with Biodentine/Formocresol in carious primary molars among children ≤ 10 years old. The risk of bias was assessed using the Cochrane RoB-2 tool. RRs and corresponding 95% CIs were calculated to pool results that RR ˃ 1 indicated a higher success rate in the Biodentine group and RR < 1 indicated a higher success rate in the Formocresol group. Heterogeneity was calculated using the I2 and τ2 statistics. In addition, trial sequential analysis was performed to adjust results for type I and type II errors and evaluate power of the meta-analysis. Results Nine RCTs were identified and eight RCTs were included in the meta-analysis and trial sequential analysis. The obtained evidence showed no significant difference between Biodentine and Formocresol in terms of clinical efficacy. However, considering the radiographic success rate the results of the meta-analysis and trial sequential analysis significantly favoured Biodentine. Conclusion Within the limitations of the present review and based on the retrieved findings it has been clearly shown that Biodentine is superior compared to Formocresol in terms of radiographic success rate with firm evidence in this regard. Although the performed meta-analysis showed no significant clinical difference between Biodentine and Formocresol, however, trial sequential analysis revealed a lack of firm evidence in this regard..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
European archives of paediatric dentistry - 23(2022), 6 vom: 20. Mai, Seite 855-867 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Firoozi, Parsa [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Biodentine |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to European Academy of Paediatric Dentistry 2022 |
|---|
| doi: |
10.1007/s40368-022-00715-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC208015978X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC208015978X | ||
| 003 | DE-627 | ||
| 005 | 20240326100046.0 | ||
| 007 | tu | ||
| 008 | 230131s2022 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40368-022-00715-9 |2 doi | |
| 035 | |a (DE-627)OLC208015978X | ||
| 035 | |a (DE-He213)s40368-022-00715-9-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Firoozi, Parsa |e verfasserin |0 (orcid)0000-0001-5595-1485 |4 aut | |
| 245 | 1 | 0 | |a Clinical and radiographic comparison of Biodentine and Formocresol: an updated meta-analysis with trial sequential analysis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to European Academy of Paediatric Dentistry 2022 | ||
| 520 | |a Purpose This meta-analysis aimed to compare the clinical and radiographic success rate of Biodentine as an alternative to Formocresol to provide a critical appraisal of the available literature and evidence-based conclusion as well as update the previous systematic review. Methods MEDLINE, CENTRAL, Web of Science, Scopus, and Google Scholar databases were searched up to 20 October 2021 to identify RCTs evaluating pulpotomy with Biodentine/Formocresol in carious primary molars among children ≤ 10 years old. The risk of bias was assessed using the Cochrane RoB-2 tool. RRs and corresponding 95% CIs were calculated to pool results that RR ˃ 1 indicated a higher success rate in the Biodentine group and RR < 1 indicated a higher success rate in the Formocresol group. Heterogeneity was calculated using the I2 and τ2 statistics. In addition, trial sequential analysis was performed to adjust results for type I and type II errors and evaluate power of the meta-analysis. Results Nine RCTs were identified and eight RCTs were included in the meta-analysis and trial sequential analysis. The obtained evidence showed no significant difference between Biodentine and Formocresol in terms of clinical efficacy. However, considering the radiographic success rate the results of the meta-analysis and trial sequential analysis significantly favoured Biodentine. Conclusion Within the limitations of the present review and based on the retrieved findings it has been clearly shown that Biodentine is superior compared to Formocresol in terms of radiographic success rate with firm evidence in this regard. Although the performed meta-analysis showed no significant clinical difference between Biodentine and Formocresol, however, trial sequential analysis revealed a lack of firm evidence in this regard. | ||
| 650 | 4 | |a Biodentine | |
| 650 | 4 | |a Formocresol | |
| 650 | 4 | |a Pulpotomy | |
| 650 | 4 | |a Paediatric dentistry | |
| 650 | 4 | |a Evidence-based dentistry | |
| 650 | 4 | |a Meta-analysis | |
| 700 | 1 | |a Salman, Bahareh Nazemi |4 aut | |
| 700 | 1 | |a Aslaminabadi, Naser |0 (orcid)0000-0002-6624-4994 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European archives of paediatric dentistry |d Springer Berlin Heidelberg, 2006 |g 23(2022), 6 vom: 20. Mai, Seite 855-867 |w (DE-627)589421352 |w (DE-600)2472851-2 |w (DE-576)394708598 |x 1818-6300 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2022 |g number:6 |g day:20 |g month:05 |g pages:855-867 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s40368-022-00715-9 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_267 | ||
| 912 | |a GBV_ILN_2018 | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2022 |e 6 |b 20 |c 05 |h 855-867 | ||